Kezar Life Sciences Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | |
| – | +13.6% | +294.3% | +88.6% | +18.7% | -2.2% | -32.3% | +4.2% | -2.4% | -206.3% | |
| – | +58.6% | +881.8% | +101.1% | +23.4% | +53.7% | +84.4% | +29.5% | -28.3% | -31.1% | |
| – | +58.6% | +934.0% | +90.9% | +23.4% | +53.7% | +84.5% | – | – | – | |
| – | – | +106.7% | +1,321.0% | -328.3% | – | -463.7% | – | -127.6% | – | |
| – | +194.7% | +187.9% | -45.8% | -68.0% | +62.9% | +399.4% | +14.7% | -98.4% | -72.4% | |
| – | +194.7% | +21,469.2% | – | -376.7% | -49.7% | +221.3% | – | +5.8% | +15.0% | |
| – | +138,108.3% | +56.6% | -99.7% | +67.6% | +357.0% | -36.7% | – | – | – | |
| – | – | – | +0.0% | +0.0% | +0.0% | -100.0% | – | – | – | |
| – | +138,108.3% | +56.6% | -99.7% | +36,533.1% | +13.0% | +13.6% | -99.5% | -83.9% | -10,376.7% | |
| – | – | -165.1% | – | – | +563.6% | -153.8% | – | – | +381.6% | |
| – | – | – | – | – | – | – | – | – | – |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.